Ifosfamide more likely to extend survival than topotecan-cyclophosphamide in Ewing sarcoma

CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide.
Martin G. McCabe, MD, PhD, clinical senior lecturer in pediatric and adolescent oncology at University of Manchester in the U.K., presented the results of the mutliarm, multistage, adaptive design phase 2/phase 3 rEECUr trial during a press briefing at ASCO Annual Meeting.
Ewing sarcoma mainly affects children and teenagers, with 5-year survival rates

CHICAGO — In what researchers described as the first randomized controlled trial of chemotherapy in relapsed or refractory Ewing sarcoma, high-dose ifosfamide proved more effective in extending survival than topotecan and cyclophosphamide.
Martin G. McCabe, MD, PhD, clinical senior lecturer in pediatric and adolescent oncology at University of Manchester in the U.K., presented the results of the mutliarm, multistage, adaptive design phase 2/phase 3 rEECUr trial during a press briefing at ASCO Annual Meeting.
Ewing sarcoma mainly affects children and teenagers, with 5-year survival rates